Description

QIAGEN’s Outlook Reset: Can Digital PCR And Sample Tech Offset QuantiFERON Weakness?

QIAGEN N.V. reported preliminary results for the first quarter of 2026, revealing a mixed performance marked by solid profitability but sales slightly below prior expectations. The company delivered adjusted diluted earnings per share (EPS) of $0.54 at constant exchange rates (CER), meeting its outlook despite a challenging macroeconomic environment and uneven sales across business segments. Total net sales were $492 million, representing a 2% increase on a reported basis but a 1% decline at CER, falling short of the targeted minimum 1% CER growth. This was primarily due to a 5% decline in QuantiFERON sales, driven by significantly reduced immigration testing demand in key markets such as the U.S. and the Middle East. The remainder of the QuantiFERON business, which encompasses about 90% of sales and is centered on patient testing, showed stable ordering and continued growth consistent with latent tuberculosis (TB) market trends.